Advertisement
Advertisement
November 19, 2026
Rhevera Marks Milestones With the Detour System for Complex PAD
KEY TAKEAWAYS
- Rhevera Medical reported that 2,000 patients have undergone PTAB with the Detour system across clinical studies and commercial use.
- The PTAB1 postmarket registry has enrolled > 260 patients to evaluate the system in complex, long-segment peripheral arterial disease.
- The Detour system has been commercially available since July 2023 and consists of the EndoCross device and Torus stent grafts.
November 19, 2026—Rhevera Medical announced that 2,000 patients have been treated with its Detour system for percutaneous transmural arterial bypass (PTAB) in long, complex superficial femoral artery disease. The total enrolled population includes patients treated in the DETOUR1 and DETOUR2 clinical studies and patients treated since the system’s commercial launch in July 2023.
According to Rhevera, PTAB with the Detour system is a minimally invasive treatment option for patients with complex peripheral artery disease (PAD). The company noted that PTAB with Detour has demonstrated sustained outcomes similar to open surgical bypass with synthetic grafts. The system is composed of the EndoCross device and Torus stent grafts.
Additionally, Rhevera reported on progress in the PTAB1 study, a postmarket, multicenter, real-world registry evaluating the safety and clinical performance of the Detour system. PTAB1 has enrolled > 260 patients and is tracking outcomes in patients with complex, long-segment PAD, noted Rhevera.
Prakash Krishnan, MD, with Icahn School of Medicine at Mount Sinai in New York, New York, performed the 2,000th procedure with the Detour system.
“Patients with long-segment disease often have limited treatment options, and the disease itself can threaten their mobility and independence,” commented Dr. Krishnan in the Rhevera press release. “Reaching 2,000 patients shows how much physician experience with PTAB has grown, particularly in cases where conventional endovascular approaches and open surgery may not fully address a patient’s clinical needs.”
In October 2026, the company announced a change in company brand identity from Endologix Holdings to Rhevera Medical. Endologix LLC remains the legal manufacturer of the company’s products.
Advertisement
Advertisement